Leclercq Mathilde, Goupillou Paul, Gomez Hélène, Muraine Marc, Benhamou Ygal, Girszyn Nicolas, Gueudry Julie
CHU Rouen, Internal Medicine Department, CHU Charles Nicolle, 1, Rue de Germont, 76000, Rouen, France.
Ophthalmology Department, CHU Rouen, 76000, Rouen, France.
J Ophthalmic Inflamm Infect. 2023 Jul 18;13(1):32. doi: 10.1186/s12348-023-00336-3.
The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available.
We report a case series of patients with chronic noninfectious uveitis with incomplete efficacy of subcutaneous tocilizumab, improved after switching to intravenous routes. Improvement of visual acuity was observed with intravenous tocilizumab for all patients. Half of the patients could stop corticosteroids. Rapid efficacy of intravenous tocilizumab was observed, between 2 and 3 months.
In uveitis, tocilizumab administration could be optimized by a switching from a subcutaneous to an intravenous administration route.
此前已有关于托珠单抗治疗难治性慢性非感染性葡萄膜炎疗效的报道，但尚无关于葡萄膜炎中静脉注射与皮下注射托珠单抗对比的数据。
我们报告了一组慢性非感染性葡萄膜炎患者的病例系列，这些患者皮下注射托珠单抗疗效不完全，改为静脉注射途径后病情改善。所有患者静脉注射托珠单抗后视力均有提高。半数患者可停用皮质类固醇。静脉注射托珠单抗在2至3个月内显示出快速疗效。
在葡萄膜炎中，可以通过从皮下给药途径转换为静脉给药途径来优化托珠单抗的给药方式。
